x
Filter:
Filters applied
- Molecular Bases of Disease
- Hazen, Stanley LRemove Hazen, Stanley L filter
- 2017 - 2022Remove 2017 - 2022 filter
Author
- DiDonato, Joseph A2
- Gogonea, Valentin2
- Huang, Ying2
- Battle, Shawna1
- Buffa, Jennifer A1
- Cameron, Scott J1
- Choucair, Ibrahim1
- Crabb, John W1
- DiDonato, Anthony J1
- Ellington, Andrew D1
- Fu, Xiaoming1
- Graham, Linda M1
- Hughes, Randall A1
- Levison, Bruce S1
- Li, Xinmin S1
- Wang, Zeneng1
- Willard, Belinda1
- Zamanian-Daryoush, Maryam1
Molecular Bases of Disease
2 Results
- Research ArticleOpen Access
The pattern of apolipoprotein A-I lysine carbamylation reflects its lipidation state and the chemical environment within human atherosclerotic aorta
Journal of Biological ChemistryVol. 298Issue 4101832Published online: March 15, 2022- Shawna Battle
- Valentin Gogonea
- Belinda Willard
- Zeneng Wang
- Xiaoming Fu
- Ying Huang
- and others
Cited in Scopus: 2Protein lysine carbamylation is an irreversible post-translational modification resulting in generation of homocitrulline (N-ε-carbamyllysine), which no longer possesses a charged ε-amino moiety. Two distinct pathways can promote protein carbamylation. One results from urea decomposition, forming an equilibrium mixture of cyanate (CNO−) and the reactive electrophile isocyanate. The second pathway involves myeloperoxidase (MPO)-catalyzed oxidation of thiocyanate (SCN−), yielding CNO− and isocyanate. - Molecular Bases of DiseaseOpen Access
Site-specific 5-hydroxytryptophan incorporation into apolipoprotein A-I impairs cholesterol efflux activity and high-density lipoprotein biogenesis
Journal of Biological ChemistryVol. 295Issue 15p4836–4848Published online: February 25, 2020- Maryam Zamanian-Daryoush
- Valentin Gogonea
- Anthony J. DiDonato
- Jennifer A. Buffa
- Ibrahim Choucair
- Bruce S. Levison
- and others
Cited in Scopus: 13Apolipoprotein A-I (apoA-I) is the major protein constituent of high-density lipoprotein (HDL) and a target of myeloperoxidase-dependent oxidation in the artery wall. In atherosclerotic lesions, apoA-I exhibits marked oxidative modifications at multiple sites, including Trp72. Site-specific mutagenesis studies have suggested, but have not conclusively shown, that oxidative modification of Trp72 of apoA-I impairs many atheroprotective properties of this lipoprotein. Herein, we used genetic code expansion technology with an engineered Saccharomyces cerevisiae tryptophanyl tRNA-synthetase (Trp-RS):suppressor tRNA pair to insert the noncanonical amino acid 5-hydroxytryptophan (5-OHTrp) at position 72 in recombinant human apoA-I and confirmed site-specific incorporation utilizing MS.